| Literature DB >> 32475837 |
Louise Freebairn1,2,3, Jo-An Atkinson4,5, Yang Qin6, Christopher J Nolan7,8, Alison L Kent8,9, Paul M Kelly3,8, Luke Penza10, Ante Prodan10, Anahita Safarishahrbijari6, Weicheng Qian6, Louise Maple-Brown11,12, Roland Dyck13, Allen McLean6, Geoff McDonnell4, Nathaniel D Osgood6.
Abstract
INTRODUCTION: Hyperglycemia in pregnancy (HIP, including gestational diabetes and pre-existing type 1 and type 2 diabetes) is increasing, with associated risks to the health of women and their babies. Strategies to manage and prevent this condition are contested. Dynamic simulation models (DSM) can test policy and program scenarios before implementation in the real world. This paper reports the development and use of an advanced DSM exploring the impact of maternal weight status interventions on incidence of HIP.Entities:
Keywords: causal modeling; gestational diabetes mellitus; modeling; population health
Mesh:
Year: 2020 PMID: 32475837 PMCID: PMC7265040 DOI: 10.1136/bmjdrc-2019-000975
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Overview of the participatory model development process.
Figure 2Overview of model components and structure. DIP, Diabetes in Pregnancy; GDM, Gestational Diabetes Mellitus; IGR, Impaired Glucose Regulation; IGT, Impaired Glucose Tolerance; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
Scenario descriptions
| Scenario | Description |
| Population intervention | This intervention targets all women aged 20–35 years through a public health intervention. The goal of the intervention is to support women to maintain or achieve a healthier weight status. |
| Targeted prepregnancy intervention | This intervention targets women who have one or more risk factor for HIP. It is available to all women who are considering pregnancy (60% of pregnancies |
| Targeted interpregnancy | This interpregnancy intervention targets women who have had diabetes in a previous pregnancy. The intervention aims to increase adherence to diet and physical activity recommendations and to achieve a healthy weight before the next pregnancy. |
| Combined | This scenario combines all the above interventions. |
HIP, hyperglycemia in pregnancy.
Summary HIP incidence statistics for baseline and scenarios simulated from 2018 to 2040
| 2020 | 2030 | 2040 | |||||||
| % | 95% CI (±) | % reduction from baseline | % | 95% CI (±) | % reduction from baseline | % | 95% CI (±) | % reduction from baseline | |
| Baseline | 15.9 | 0.4 | – | 16.1 | 0.3 | – | 17.3 | 0.4 | – |
| 1. Population intervention | 15.5 | 0.4 | −3.0 | 13.3* | 0.3 | −17.6 | 13.8* | 0.3 | −20.5 |
| 2. Targeted prepregnancy | 15.5 | 0.3 | −2.8 | 15.3* | 0.3 | −5.2 | 16.2* | 0.4 | −6.2 |
| 3. Targeted interpregnancy reduction | 15.6 | 0.3 | −2.1 | 15.5* | 0.3 | −4.2 | 16.7* | 0.4 | −3.8 |
| 4. Combined population and targeted prepregnancy and interpregnancy | 13.6 | 0.4 | −14.4 | 11.5* | 0.3 | −28.8 | 11.8* | 0.3 | −32.1 |
*Significantly different from baseline at p<0.05.
HIP, hyperglycemia in pregnancy.
Figure 3Comparative impact of scenarios on HIP incidence simulated from 2018 to 2040. Dotted lines indicate 95% CI for estimated incidence. HIP, hyperglycemia in pregnancy.
Summary HIP (percentage) incidence and population insulin sensitivity (KxgI) statistics for baseline and scaling up and scaling back scenarios simulated from 2018 to 2060
| HIP incidence (%) | 2020 | 2030 | 2040 | 2050 | 2060 | ||||||||||
| % | 95% CI (±) | % change from baseline | % | 95% CI (±) | % change from baseline | % | 95% CI (±) | % change from baseline | % | 95% CI (±) | % change from baseline | % | 95% CI (±) | % change from baseline | |
| Baseline | 15.6 | 0.28 | 15.8 | 0.31 | 16.9 | 0.31 | 17.2 | 0.3 | 17.0 | 0.3 | |||||
| Scenario A: all normal weight | 15.9 | 0.26 | 1.8 | 15.9 | 0.31 | 0.8 | 17.1 | 0.31 | 1.4 | 17.0 | 0.3 | −0.9 | 13.4* | 0.3 | −21.2 |
| Scenario B: more overweight or obese | 15.7 | 0.27 | 0.4 | 15.7 | 0.30 | −0.6 | 17.1 | 0.27 | 1.3 | 17.3 | 0.3 | 0.4 | 17.6 | 0.3 | 3.8 |
KxgI: an index of insulin sensitivity representing insulin-dependent glucose tissue reuptake.
*Significantly different from baseline at p<0.05.
HIP, hyperglycemia in pregnancy.